Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px
Document › Details

genOway S.A.. (10/30/19). "Press Release: The Institut Pasteur and Cellectis Extend Exclusive License Rights by Granting genOway the Authority to Take Action against Infringement". Lyon & Paris.

Region Region United States (USA)
Organisations Organisation genOway S.A. (Euronext Growth: ALGEN)
  Group genOway (Group)
  Organisation 2 Institut Pasteur
Products Product transgenic animal
  Product 2 animal model
Index term Index term genOway–Institut Pasteur: transgenic anmials, 201910– license extension from IP + Cellectis to genOway to take legal actions against infringement
Persons Person Fraichard, Alexandre (genOway 200610 CEO + Co-Founder)
  Person 2 Choulika, André (Cellectis 200701 CEO + co-founder)
     


> The research models developed using Homologous Recombination Technology (such as those protected by US patents US6528313, US6638768, and US6528314 deposited by the Institut Pasteur) are essential tools for pharmaceutical research.

> Due to its knowledge of the needs of preclinical programs, as well as its exclusive rights on this patent portfolio granted in 2014, genOway is the best partner to enable the industry to benefit most from this technology while ensuring fair remuneration of its exploitation.


The Institut Pasteur, a non-profit foundation with recognized charitable status and an internationally renowned center of biomedical research, Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), and genOway, a public company leader in conceiving and developing genetically modified research models, announce the extension of genOway's exclusive rodent license to the patent portfolio of Homologous Recombination, granted in 2014, to allow genOway to take action to protect against infringement.

The patent portfolio of Homologous Recombination (US6528313, US6638768, and US6528314) enables the development of research models essential for both target validation and preclinical evaluation of drug candidates. Indeed, its most important application is to humanize targets in animal models in order to study the activity, specificity and safety of drug candidates, from small molecules to therapeutic antibodies. This is achieved through the interaction between the drug candidate and the human protein, thus mimicking what naturally occurs in the patient.

The scientific value of these models is important and, as such, it deserves fair remuneration. The extension of the rights granted to genOway enables the latter to act against infringement from this day and up to six years after the end of the patent, i.e., 2026.

“We are delighted to strengthen our relationships with Cellectis and the Institut Pasteur. These new rights will enable us to serve our customers better, and guarantee a fair valorization of the applications of our partnerships with the Institut Pasteur and Cellectis,” says Alexandre Fraichard, founder and Chief Operating Officer of genOway.

“Cellectis has always paid particular attention to intellectual property rights and we wish to help genOway, our exclusive licensee for the past five years, do the same. This transfer of rights provides genOway the potential to develop more resources and sell this technology, while protecting themselves against infringement,” says Dr André Choulika, Chairman and Chief Executive Officer of Cellectis.

“The technologies and innovations developed by the research teams of the Institut Pasteur are meant to benefit the entire scientific community. However, it is also important that a fair valorization is received for the applications we invented in the past, as these revenues are essential to our current research programs. We support genOway and we will continue to do so, as it is our exclusive licensee of this technology for animal models,” says Dr Isabelle Buckle, Director of Research Applications and Industrial Relations at the Institut Pasteur.


About genOway

genOway (Euronext Growth®: ALGEN; ISIN: FR0004053510) is a biotechnology society which aims to conceive and develop high value-added molecular, cellular and animal research models for biopharmaceutical, chemical, agrochemical and food industries, as well as academic research. With highly qualified scientific personnel, genOway operates in 28 countries in Europe, Asia and North America, and more than 260 research institutes and 80 biopharmaceutical companies. genOway is a market leader in terms of both size and customer portfolios. The company’s development is based on a broad and exclusive technology platform, as well as on strong intellectual property rights, combining patents and licensing agreements. Taking advantage of the global trend toward outsourcing the production of genetically modified research models, genOway has signed many commercial contracts with the leaders of the pharmaceutical industry (BMS, Janssen, Novartis, Pfizer, etc.), and with the most prestigious academic research centers, including King’s College London and the University of Manchester in England; Harvard, Caltech and the National Institutes of Health in the United States; the Pasteur Institute in France; the German National Genome Research Network and the Max Planck Institute in Germany. To find out more about genOway, visit: www.genOway.com

Contact business: licensing@genoway.com
Investor contact: Benjamin Bruneau – genOway – finances@genoway.com
Financial Communication Agency: Mathieu Omnes – Actus – Phone: +33 (0)1 53 67 36 92 – momnes@actus.fr


About Cellectis

Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 19 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL), multiple myeloma (MM), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN® is a registered trademark owned by Cellectis.


About the Pasteur Institute

The Institut Pasteur, a non-profit foundation with recognized charitable status set up by Louis Pasteur in 1887, is today an internationally renowned center for biomedical research with a network of 32 institutes worldwide. In the pursuit of its mission to prevent and control diseases in France and throughout the world, the Institut Pasteur operates in four main areas: research, public health, education and training, and development of research applications. More than 2,700 people work on its Paris campus. The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology. Other avenues of investigation include cancer, genetic and neurodegenerative diseases, genomics and developmental biology. This research aims to expand our knowledge of the living world in a bid to lay the foundations for new prevention strategies and novel therapeutics. Since its inception, 10 Institut Pasteur scientists have been awarded the Nobel Prize for Medicine, including two in 2008 for the 1983 discovery of the human immunodeficiency virus (HIV) that causes AIDS. www.pasteur.fr/en


The information presented in this document may contain forward-looking statements involving risks and uncertainties. The actual achievements of the Company may be substantially different from those anticipated in this document because of the risk factors related to the company. www.genoway.com.

   
Record changed: 2019-11-07

Advertisement

Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

More documents for genOway (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2019 Partnering Report BEU2019 650x80px




» top